B7H3/CD19 dual targeted CAR-T (Seattle Children'S Hospital)

B7H3/CD19双靶向CAR-T (Seattle Children'S Hospital)

Report date: 2026/05/09 20:00:18

Base Information

Drug NameB7H3/CD19 dual targeted CAR-T (Seattle Children'S Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsAnti-CD276Anti-CD19
TargetsCD276 antigenB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursCarcinomaMelanoma +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinomaMelanoma +[17] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A